Breakthrough drug targets liver regeneration with 21.5m boost
Longevity Technology - 17-Apr-2025HepaRegeniX advances trials for a novel liver regeneration therapy
HepaRegeniX
Developing liver diseases treatment
HepaRegeniX GmbH is a clinical stage company developing novel therapies for the treatment of acute and chronic liver diseases. Since its start in 2017, HepaRegeniX has successfully discovered and developed several drug candidates for the treatment of acute and chronic liver diseases based on a novel proprietary molecular target Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).
Visit website: https://www.heparegenix.com/
Details last updated 08-Apr-2024
HepaRegeniX News
HepaRegenix secures 15M euros to advance regenerative liver therapy
Longevity Technology - 15-Jul-2024Funding fuels clinical trials of a lead compound, offering hope for liver disease patients
A new drug targeting liver cell growth shows excellent safety results in humans
HepaRegeniX GmbH - 15-Mar-2024This could change the way we treat liver cancer and address transplant organ shortages
HepaRegeniX raised €11M to fund clinical trials for a drug that regenerates liver
Labiotech - 21-Jan-2021This treatment could help in cases of severe liver disease, like NASH
